Loading...
This record has been deleted. Since it is linked to a published record, it is available here for reference purposes only.
Click here to view the deleted recordThis document has been updated. This is not the latest published version. Click here to view the latest version of the record.
Living Modified Organism
(LMO)
The image below identifies the LMO through its unique identifier, trade name and a link to this page of the BCH. Click on it to download a larger image on your computer. For help on how to use it go to the LMO quick-links page.
Telomelysin®
EN
OBP-301
No
-
Organization:Oncolys BioPharma Inc ()Toranomon Towers Office, 4-1-28 Toranomon, Minato-kuTokyo,
105-0001, JapanPhone:Fax:Email:Website: http://www.oncolys.com/en/,
Telomelysin or OBP-301 is oncolytic adenovirus in which the wild-type viral DNA is modified to be able to selectively replicate in cancer cells by introducing human telomerase reverse transcriptase (hTERT) promotor. Oncolytic adenovirus has much potential for cancer immunotherapy because its viral replication is highly immunogenic, and oncolysis induced by such virus releases tumor epitopes and provides costimulatory danger signals.
EN
The term “Recipient organism” refers to an organism (either already modified or non-modified) that was subjected to genetic modification, whereas “Parental organisms” refers to those that were involved in cross breeding or cell fusion.
-
BCH-ORGA-SCBD-113222-2 Organism Human mastadenovirus C, type 5 (HAdV-C)Viruses
EN
phTERT-E1A-IRES-E1B
EN
- Other (Transfection)
Some of these genetic elements may be present as fragments or truncated forms. Please see notes below, where applicable.
-
BCH-GENE-SCBD-113224-1 Telomerase reverse transcriptase gene promoter | Homo sapiens (HUMAN)Promoter
-
BCH-GENE-SCBD-113226-1 Internal Ribosome Entry Sequence | Cardiovirus A (Cardiovirus A, EMCV)Promoter
The Adenovirus Type 5 virus was genetically modified by the deletion of the wild-type E1 transcriptional unit and replacing it with a 3843 base pair insertion comprising a new E1 transcriptional unit in which the native adenovirus E1 transcriptional promoter is replaced by the human telomerase reverse transcriptase (hTERT) promoter, and an internal ribosome entry sequence (IRES) is inserted between the E1A and E1B genes.
EN
EN
- Pharmaceutical
EN
EN
| Record type | Field | Record(s) | |
|---|---|---|---|
| Country's Decision or any other Communication | LMO identification | 1 | |
| Risk Assessment generated by a regulatory process | Living modified organism(s) | 1 | |
